Biomarkers From Discovery To Validation

Biomarker development is a continuous process. From the discovery of biomarkers to biomarker application, it is necessary to pass through the process of candidate biomarker optimization, potential biomarker verification and biomarker verification. Among other things, validation of potential biomarkers requires that their levels change in a consistent and statistically significant manner in response to a disease, condition, or other parameter. Identification and characterization of potential biomarkers can reduce the number of drug candidates that fail clinical trials. This will aid in the discovery of more effective treatments, and provide a means of monitoring animals in preclinical studies and assessing the response of human participants in trials.

Fig. 1. Workflow for Biomarker Discovery and Validation Process. (Del Boccio P, et al., 2016)

Services Overview

Ace Therapeutics has a dedicated team of ophthalmology researchers and biomarkers dedicated to contributing to the ophthalmic research of its partners. Here, we provide quality potential ocular biomarker validation services to global clients.

Ace Therapeutics offers several strategies for the validation of potential biomarkers: bioanalytical validation, laboratory-developed tests, in vitro diagnostics, and so on. Ace Therapeutics performs a validated analysis of potential biomarkers using enzyme-linked immunoassay (ELISA), lateral flow immunoassay (LF) and immunohistochemistry (IHC) as well as liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS), polymerase chain reactio(PCR) and western blot biomarker detection platforms. Our scientists perform pre-validation testing of ocular biomarker assays using calibration standards and quality controls to analyze some customer samples in duplicate. After initial biomarker development is complete, our scientists will select the most appropriate validation strategy considering the intended use of your biomarker in drug development. This will demonstrate methodological reliability for the intended use.

Considering different types of assays, Ace Therapeutics has developed a variety of technology platforms for potential biomarker validation, including LC-MS/MS, Ligand Binding Analysis (LBA), and flow cytometry. Based on the client's project, analyte type, proposed platform, regulatory requirements, and availability of reagents, our expert team customizes a personalized analysis strategy. Our potential biomarker-free validation services include, but are not limited to.

• Potential ocular biomarker sensitivity testing service.
• Potential ocular biomarker specific testing services.
• Potential ocular biomarker precision testing service.
• Large sample verification service.

Our Experience

• Liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS).
• Polymerase chain reaction (PCR).
• Western blot (WB).
• Next generation sequencing (NGS).
• CRISPR-Cas9 gene editing.
• Enzyme-linked immunosorbent assay (ELISA).
• Lateral flow analysis (LF).
• Immunohistochemistry (IHC).
• Various microarrays.

Service Highlights

• Reduce the number of drug candidates that have not passed clinical validation through advanced high-throughput technology platforms and multiple analysis strategies.
• Apply the most appropriate computer framework to data analysis through bioinformatics to improve the chances of clinical success.
• Provide specific and sensitive biomarker verification services.
• Enhance the development of validation assays for potential biomarkers such as ELISA, LC-MS/MS, qPCR, Western Blot, etc.
• Provide complete experimental data and comprehensive analysis reports.
• Provide high-quality and efficient customized services according to customer needs.

A corresponding team of experts is responsible for all of our services. To obtain the most suitable resources and customized potential ocular biomarker validation solutions, please contact us at any time.

Workflow of Ocular Biomarker Custom Services at Ace Therapeutics.

Ace Therapeutics' ocular biomarker research team provides global customers with high-quality customized services related to potential ocular biomarker validation. Our scientists can customize scientific and rigorous laboratory plans according to the research needs and sample types of customers. If you are looking for related services, Ace Therapeutics may be your ideal partner. Please feel free to contact us for more information.

Reference

1. Del Boccio P, Rossi C, di Ioia M, et al. Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine. Proteomics Clin Appl. 2016r;10(4):470-84.

• In Vitro Screening Services for Ocular Biomarkers
• In Vivo Screening Services for Ocular Biomarkers
• Ocular Candidate Biomarker Optimization Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit